Valuation: Red Light Holland Corp.

Market Cap 18.42M 12.98M 11.45M 10.84M 9.83M 1.25B 18.61M 130M 50.1M 636M 48.73M 47.67M 2.05B P/E 2025
-2.98x
P/E 2026 -1.71x
Enterprise Value 10.19M 7.18M 6.34M 5.99M 5.44M 689M 10.29M 71.91M 27.71M 352M 26.96M 26.37M 1.13B EV / Sales 2025
0.29x
EV / Sales 2026 0.57x
Free-Float
94.1%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer - 2020-05-21
Director of Finance/CFO - 2026-08-18
President 40 -
Director TitleAgeSince
Chairman - 1982-09-28
Chairman - 2020-05-24
Director/Board Member 31 2019-02-28
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 12.98M
+1.14%+1.21%-19.44%-13.23% 14.95B
-1.82%-3.14%-4.42%+4.35% 5.25B
-2.26%-2.01%-10.14%+7.54% 3.56B
+1.36%+5.06%-49.18%+1,856.07% 2.99B
-0.99%-10.69%+3.24%+26.26% 2.63B
-0.26%+8.26%+76.74%+114.08% 2.26B
-3.16%-1.26% - - 1.91B
+1.72%0.00%+34.09%+9.77% 1.8B
+5.41%-6.89%+13.45%-4.32% 1.59B
Average +0.25%-1.12%+5.54%+250.06% 4.1B
Weighted average by Cap. +0.26%-0.29%-6.64%+163.88%

Financials

2025 2026
Net sales 4.94M 3.48M 3.07M 2.91M 2.64M 334M 4.99M 34.89M 13.45M 171M 13.08M 12.79M 549M 4.2M 2.96M 2.61M 2.47M 2.24M 284M 4.24M 29.6M 11.41M 145M 11.1M 10.86M 466M
Net income -4.04M -2.85M -2.51M -2.38M -2.16M -273M -4.08M -28.52M -10.99M -140M -10.69M -10.46M -449M -6.1M -4.3M -3.79M -3.59M -3.25M -412M -6.16M -43.05M -16.59M -211M -16.14M -15.79M -678M
Net Debt -10.87M -7.66M -6.76M -6.39M -5.8M -735M -10.98M -76.68M -29.55M -375M -28.75M -28.12M -1.21B -8.23M -5.8M -5.12M -4.84M -4.39M -556M -8.31M -58.08M -22.39M -284M -21.77M -21.3M -914M
Logo Red Light Holland Corp.
Rhelion Life Sciences Corp., formerly Red Light Holland Corp., is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the Company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with institutions around the world. PEX010 is its standardized natural psilocybin drug candidate, studied across 80+ clinical trials worldwide, including FDA-authorized programs in depression, PTSD, cancer-related distress, and substance use disorders. Its products also include IBEXX and MB2500. IBEXX is its botanical ibogaine drug candidate. MB2500 is its whole-leaf coca extract drug candidate. It also operates in the Netherlands' legal adult-use market and supports voluntary data collection and research to help advance the scientific understanding of natural psychedelics.
Employees
-